arrow
F

Fumihiko Urabe

jikei university
H指数:18
被引数:2,138

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic impact of large cribriform architecture and intraductal carcinoma of the prostate in diagnostic biopsies of mCSPC receiving ARPI-based therapy

前列腺中分化腺癌和导管内癌在诊断性活检中对接受ARPI为基础治疗的前列腺癌患者的预后影响

2026-08-010
PRE
Author's reply to 'Bayesian interpretation of febrile neutropenia risk and primary G-CSF prophylaxis during darolutamide triplet therapy'

作者回复:“达罗鲁胺三联疗法期间发热性中性粒细胞减少症风险和初级G-CSF预防的贝叶斯解释”

2026-08-010
PRE
Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)

基线疾病特征和铂类药物敏感性作为顺铂为基础化疗、阿维鲁姆单抗维持治疗和恩沃利单抗维多汀序贯疗法在晚期尿路上皮癌中的预后预测因素(ARON-2EV研究)

2026-07-290
PRE
Real-world evaluation of primary prophylactic use of granulocyte colony-stimulating factor in patients with metastatic castration-sensitive prostate cancer treated with triplet therapy

转移性去势敏感前列腺癌患者接受三联疗法时,粒细胞集落刺激因子一级预防性使用的真实世界评估

2026-07-150
PRE
Sympathetic reinnervation is associated with antihypertensive treatment burden and interstitial fibrosis after kidney transplantation

交感神经再支配与肾移植后抗高血压治疗负担及间质纤维化相关

2026-05-150
OAAI
REAL-WORLD OUTCOMES OF IO-BASED FIRST-LINE THERAPY IN METASTATIC RENAL CELL CARCINOMA PATIENTS ON HEMODIALYSIS

IO-Based一线疗法在行血液透析的转移性肾细胞癌患者中的真实世界疗效

2026-05-010
PRE
NIVOLUMAB PLUS CABOZANTINIB VERSUS PEMBROLIZUMAB PLUS LENVATINIB FOR METASTATIC RENAL CELL CARCINOMA: A PROPENSITY SCORE-MATCHED ANALYSIS OF JAPANESE MULTICENTER DATABASE

纳武利尤单抗联合卡博替尼与帕博利珠单抗联合仑伐替尼治疗转移性肾细胞癌:基于日本多中心数据库的倾向性评分匹配分析

2026-05-010
PRE
Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features

前列腺癌诊断时循环神经内分泌肿瘤标志物的评估:一项针对具有神经内分泌特征的前列腺癌的研究

2026-04-170
PRE
Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer

根治性膀胱切除术治疗非肌层浸润性膀胱癌的肿瘤学结果综合分析

2026-04-050
OAAI
Prognostic Factors of Trimodal Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis

肌层浸润性膀胱癌三联疗法的预后因素:一项系统评价和Meta分析

2025-12-180
OAAI
Clinical profiles and predictors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer receiving denosumab

转移性去势抵抗性前列腺癌患者中症状性骨骼事件的临床特征和预测因子,在接受地诺单抗治疗时。

2025-12-090
PRE
Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis

新辅助化疗在肌层浸润性膀胱癌三模式治疗前的应用:系统评价与Meta分析

2025-12-040
OAAI
Rapidly progressive and fatal drug-induced interstitial pneumonitis after three cycles of enfortumab vedotin plus pembrolizumab treatment for metastatic urothelial carcinoma: a case report

快速进展且致命的药物性间质性肺炎,发生于接受恩沃利单抗 vedotin 联合帕博利珠单抗治疗转移性尿路上皮癌3个周期后:病例报告

2025-12-010
PRE
The Impact of Early Modification of Upfront Androgen Receptor Signaling Inhibitors on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer

早期调整一线雄激素受体信号抑制剂对转移性激素敏感性前列腺癌生存结局的影响

2025-11-060
PRE